Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc ACHFF


Primary Symbol: V.ARCH

Technology Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Bullboard (TSXV:ARCH)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by Arbourmarkon Dec 12, 2022 1:20pm

RE:Arch - Dramatically Undervalued in comparison to its peers

There is no doubt ARCH is under valued and that the science is solid. The biggest concern is lack of news and communication from management and why the other companies are valued a such a premium from ...more  
113
Discussion
Post by Riverfolkon Dec 12, 2022 12:18pm

Arch Biopartners - My Due Diligence

Arch Biopartners - My Due Diligence Arch Biopartners Inc. (“Arch” or the “Company”) is a portfolio-based biotechnology company focused on the development of innovative technologies that have the ...more  
183
Discussion
Post by Riverfolkon Dec 12, 2022 12:07pm

Arch - Dramatically Undervalued in comparison to its peers

Companies w/ Positive Phase II Data: $Arch.v $Achff @archbiopartners - $122,000,000 @ $2.90 Positive Phase II Data ( Organ Inflammation ) (TSXV) $BLU - $1,691,000,000 @ $13.52 ( Chronic Cough ...more  
103
Discussion
Post by Arbourmarkon Dec 08, 2022 10:01am

Unusual Volume Again

Once again another day passes with no communication or updates from management and volume again unusually high at 16,000 shares. Someone selling but someone buying.
106
Comment by TheBearInTheWoodson Dec 08, 2022 12:52am

RE:Tax Loss Selling

Yesterday the stock was up 6%, today it's down. Which day do you post? The stock is flat year over year at the moment and financials show no need for money. If you can handle the heat maybe sell ...more  
101
Discussion
Post by Arbourmarkon Dec 07, 2022 3:53pm

Tax Loss Selling

Above average volume on both US side and Canadian. Close to 50,000 shares sold. I suspect that many purchased shares at higher price but with no news or updates in past 9 months has investors ...more  
146
Discussion
Comment by Cb27743on Dec 06, 2022 6:09pm

RE:RE:RE:RE:RE:Silence

I hear your frustration,   We are still waiting for reviewed data from their completed 2021 P2 trial which usually takes 6 from what I heard on another market platform. The last update we ...more  
119
Discussion
Comment by Arbourmarkon Dec 06, 2022 9:29am

RE:RE:RE:RE:Silence

Well another week and continued silence from Management. Was CATCO study positive?? Unknown. Study was approved I believe in February. When was the final dosing completed? Are the final results in? ...more  
88
Discussion
Comment by Arbourmarkon Dec 02, 2022 2:55pm

RE:RE:RE:RE:Silence

Well said.  
33
Discussion
Comment by Riverfolkon Dec 01, 2022 12:27pm

RE:RE:RE:RE:Silence

I can understand your frustration in a bear market but if there were material changes the company would have to disclose. I am invested in Arch because the company doesn't raise money (Diluting ...more  
91
Discussion
Comment by Cb27743on Dec 01, 2022 11:12am

RE:RE:RE:Silence

River,  What I am referrring to is not creating fluff news from management, but being transparent to the public regarding the current trial (if they can) and completed P2 trial. There must of ...more  
137
Discussion
Comment by Riverfolkon Dec 01, 2022 9:02am

RE:RE:Silence

The phase II clinical trial process averages 3.6 years from planning-execution-data. I am from the school of thought that no news is good news and when material items happen they will be announced ...more  
75
Discussion
Comment by Cb27743on Nov 30, 2022 11:41pm

RE:Silence

I am with you and bunch of other investors are as well. I have been with Arch since 2020 and have been very patient this 2022 year. I understand waiting on regulation can test patience in this sector, ...more  
95
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities